[3] Viardot A, Bargou R. Bispecific antibodies in haematological malignancies. Cancer Treat Rev. 2018;65:87-95. doi:10.1016/j.ctrv.2018.04.002

[4] Pytlik R, Polgarova K, Karolova J, Klener P. Current Immunotherapy Approaches in Non-Hodgkin Lymphomas. Vaccines (Basel). 2020;8(4):708. Published 2020 Nov 27. doi:10.3390/vaccines8040708

[5] Sun LL, Ellerman D, Mathieu M, et al. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med. 2015;7(287):287ra70. doi:10.1126/scitranslmed.aaa4802

[6] Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial [published online ahead of print, 2021 Mar 19]. J Clin Oncol. 2021;JCO2003175. doi:10.1200/JCO.20.03175

[7] Lussana F, Gritti G, Rambaldi A. Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies. J Clin Oncol. 2021;39(5):444-455. doi:10.1200/JCO.20.01564

[8] Muhammed Y. The Best IgG Subclass for the Development of Therapeutics Monoclonal Antibodies Drugs and their Commercial Production: A Review. Immunome Res. 2020;16(1):173. doi: 10.35248/1745-7580.20.16.173

[9] Bacac M, Colombetti S, Herter S, et al. CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies. Clin Cancer Res. 2018;24(19):4785-4797. doi:10.1158/1078-0432.CCR-18-0455

[10] Morcos PN, Li J, Hosseini I, Li CC. Quantitative Clinical Pharmacology of T-Cell Engaging Bispecifics: Current Perspectives and Opportunities. Clin Transl Sci. 2021;14(1):75-85. doi:10.1111/cts.12877

[11] Wu Z, Cheung NV. T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics. Pharmacol Ther. 2018;182:161-175. doi:10.1016/j.pharmthera.2017.08.005

[12] Cremasco F, Menietti E, Speziale D, et al. Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model. PLoS One. 2021;16(1):e0241091. Published 2021 Jan 6. doi:10.1371/journal.pone.0241091

[13] Klein C, Sustmann C, Thomas M, et al. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs. 2012;4(6):653-663. doi:10.4161/mabs.21379

[14] Lejeune M, Köse MC, Duray E, Einsele H, Beguin Y, Caers J. Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. Front Immunol. 2020;11:762. Published 2020 May 7. doi:10.3389/fimmu.2020.00762

[15] Lussana F, Gritti G, Rambaldi A. Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies. J Clin Oncol. 2021;39(5):444-455. doi:10.1200/JCO.20.01564

[16] Levine BL, Miskin J, Wonnacott K, Keir C. Global Manufacturing of CAR T Cell Therapy. Mol Ther Methods Clin Dev. 2016;4:92-101. Published 2016 Dec 31. doi:10.1016/j.omtm.2016.12.006

[17] Riedell PA, Walling C, Nastoupil LJ, et al. A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas. Blood. 2019; 134 (Supplement_1): 1599.  doi: https://doi.org/10.1182/blood-2019-127490

[18] Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B. 2018;8(4):539-551. doi:10.1016/j.apsb.2018.03.001

[19] Schuster SJ, Bartlett NL, Assouline S, et al. Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. Blood. 2019;134 (Supplement_1): 6. doi: https://doi.org/10.1182/blood-2019-123742

[20] Jacobson CA, Hunter BD, Redd R, et al. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. J Clin Oncol. 2020;38(27):3095-3106. doi:10.1200/JCO.19.02103

[21] Di M, Huntington SF, Olszewski AJ. Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients. Oncologist. 2021;26(2):120-132. doi:10.1002/onco.13610